Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Taylor Brooks, Agrima Mian, Adrienne Nedved, Yucai Wang, Natalie Grover, XI Yang, Yasmin Karimi, Tenley Schwarz, Matthew Schwede, Marshall McKenna, Yun Kyoung Tiger, Nayef Abdel-Razeq, Muhamad Alhaj Moustafa, Catherine Reinert, Ajay Major, Daniel Trotier, Priyanka Pophali, Kelsey Baron, Boyu Hu, Sally Jones, Aditi Saha, Nikita Dave, Daniel Landsburg, Megan Sears-Smith, Nilanjan Ghosh, Kiarash Salafian, Emily Ayers, Suchitra Sundaram, Joshua Brody, Alyssa Gibson, Justin Kline, Javier Munoz, Rodolfo Garza Morales, Eiraj Khan, Cyrus Khan, Brenda Castillo, Stephen Smith, Fadzai Chinyengetere, Sandeep Dave, Alex Niu, Francisco Hernandez-Ilizaliturri, Paolo Caimi, Brian Hill
Institutions: Cleveland Clinic, Mayo Clinic, UNC Lineberger Comprehensive Cancer Center, University of Michigan, Rutgers Cancer Institute, Mayo Clinic in Florida, University of Colorado Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Utah, Huntsman Cancer Institute, University of Alabama at Birmingham, University of Pennsylvania, Levine Cancer Institute, University of Virginia, Icahn School of Medicine at Mount Sinai, University of Chicago, Allegheny Health Network, Fred Hutch Cancer Center, Duke University, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417006961